Inhibiting lysosomal aldolase: a magic bullet for AMPK activation in treating metabolic disease?

Abstract

In a tour-de-force study by Zhang and colleagues recently published in Nature Metabolism, a newly identified aldolase inhibitor, Aldometanib, is shown to activate lysosomal AMPK. Remarkably, mice treated with Aldometanib have increased insulin sensitivity, lowered blood glucose, decreased hepatic steatosis and fibrosis and are long-lived, effects of which all appear to be mediated via activation of lysosomal AMPK.